-

ArsenalBio to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--ArsenalBio, a privately held programmable cell therapy company focused on building advanced CAR T therapies for solid tumors, today announced that Company leadership will participate in two upcoming virtual investor conferences:

  • Piper Sandler 33rd Annual Virtual Healthcare Conference
    Format:
    On-Demand Presentation
    Date: November 29 – December 2, 2021
    The webcast of the pre-recorded company presentation will be made available on-demand starting on Monday, November 22, 2021 at 10:00 a.m. ET
    Webcast: Link
  • Evercore ISI’s 4th Annual HealthCONx Conference
    Format:
    Live Presentation
    Date: December 2, 2021
    Time: 8:25 a.m. ET

About ArsenalBio

ArsenalBio is a privately held, programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer. Our discovery engine comprises precise CRISPR-enabled genome editing, integrated circuits incorporating logic gates for improved tumor targeting, and therapeutic enhancements enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. Our team is engineering living medicines to attack cancer’s inherent multi-faceted nature and bring dramatic improvements to the lives of patients. To learn more, visit www.arsenalbio.com and follow us on Twitter @ArsenalBio, LinkedIn and Facebook.

Contacts

Heidi Chokeir, Ph.D.
Canale Communications
619-203-5391
heidi.chokeir@canalecomm.com

ArsenalBio


Release Summary
ArsenalBio to Participate in Upcoming Investor Conferences
Release Versions

Contacts

Heidi Chokeir, Ph.D.
Canale Communications
619-203-5391
heidi.chokeir@canalecomm.com

More News From ArsenalBio

ArsenalBio Announces Expansion of Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Arsenal Biosciences, Inc., a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised an option to initiate a new program, expanding its strategic collaboration with ArsenalBio to discover and advance next-generation T cell therapies for the treatment of solid tumors. “The decision by Bristol Myers Squibb to expand our collaboration and...

ArsenalBio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--ArsenalBio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference...

ArsenalBio Announces Participation in Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--ArsenalBio, a privately held programmable cell therapy company focused on building advanced CAR T therapies for solid tumors, today announced that it will present pre-clinical data from AB-X, the company’s integrated circuit T cell therapy program for the treatment of ovarian cancer (OC), at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting taking place November 10-14, 2021 in Washington D.C., and virtually. The accepted abstract...
Back to Newsroom